Beacon | Interview with Dr James Campbell
0
Patrys CEO and MD, Dr James Campbell, has been interviewed by the drug development experts Beacon Intelligence about the Company’s…
$7.8m Capital Raise
Patrys has today announced a $7.8 million capital raising via a Placement and fully underwritten Rights Issue. These funds will…
Change of Company Secretary
Patrys is today welcoming the appointment of a new Company Secretary to our Senior Management Team, Stefan Ross, who was…
Video Presentation | AusBiotech Investor Presentation
Patrys’ CEO and MD, Dr James Campbell joined other biotech executives at the Australia Biotech Invest & Partnering Conference this…
Important Notice – Fraudulent Emails
Patrys Ltd has been informed that fraudulent emails purporting to be sent from our Company are in circulation. The fraudulent…
Quarterly Activities Report and 4C Quarterly Cash Flow Report
Patrys (ASX:PAB) has today published its Quarterly Activities Report and 4C Quarterly Cash Flow Report, for the quarter ended 30…
AusBiotech Conference | Australia Biotech Invest & Partnering Conference
Patrys CEO, Dr James Campbell, has composed some thoughts about his participation in AusBiotech’s upcoming events – the annual AusBiotech…
Patrys PATDX3 antibody drug conjugate significantly increases survival in animal model
Patrys today released the latest data from its completed proof-of-concept study demonstrating the potential of its full-sized deoxymab antibody, PAT-DX3,…
Patrys AGM – 5th Nov 2021
The Patrys Ltd team is pleased to invite you to a virtual webinar for our Annual General Meeting (AGM): WHEN:…
Video Presentation | Proactive Lifesciences Webinar
Patrys CEO and MD, Dr James Campbell, recently participated in a webinar hosted by Proactive to summarise Patrys’ key value…